Click on image to view larger version.

Figure 1 Study Design of the ARMYDA-ACS Trial

ARMYDA-ACS = Atorvastatin for Reduction of MYocardial Damage During Angioplasty—Acute Coronary Syndromes; CK-MB = creatine kinase-MB; CRP = C-reactive protein; MI = myocardial infarction; NSTE-ACS = non–ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; TVR = target vessel revascularization.